Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
Key Highlights
- ➤$105.8 million debt eliminated through conversion into 34,376,167 common shares
- ➤Phase 3 belapectin protocol submitted to FDA after trial-design alignment
- ➤$11.7 million cash plus $10 million credit availability funds operations through June 2027
- ➤Q3 net loss narrowed to $3.6 million, or $0.04 per share
- ➤Belapectin showed 15.9% placebo-adjusted improvement in predicted CSPH risk at 18 months
Expert Statements
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“We thank all the authors for their contributions, particularly to Dr. Naim Alkhouri for the oral presentation on ANTICIPATE-NASH.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“As previously disclosed, we submitted our registrational Phase 3 protocol to the FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”
Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Summit Clinical Research and Director of Steatotic Liver Program at Clinical Research Institute of Ohio
“The oral presentation, presented by Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Summit Clinical Research and Director of Steatotic Liver Program at Clinical Research Institute of Ohio, showed the potential utility of ANTICIPATE-NASH risk stratification, a validated noninvasive tool to predict variceal development and assess belapectin treatment effect.”
NORCROSS, Ga., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026.
“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics. “We thank all the authors for their contributions, particularly to Dr. Naim Alkhouri for the oral presentation on ANTICIPATE-NASH.”
Get started
Create a free account to read the full story.
